S23 (S-23)
SARMS-23
S23 is one of the most potent SARMs with HPTA suppression close to steroids. Formerly studied as a male contraceptive (at high doses). Full PCT mandatory. Reserved for experienced SARMs users.
Half-life
11,9 heures
Detection
6–8 semaines
Anabolic ratio
100
Androgenic ratio
20
Dosages
| Beginner | 5–10 mg/j |
| Intermediate | 15–20 mg/j |
| Advanced | 25–30 mg/j |
| Female | 2.5-5 mg/day |
Frequency : 1-2× / day
Effects
- One of the most anabolic SARMs
- Significant lean gains
- Hardness
- Cutting
Side effects
- Very strong HPTA suppression (close to steroids)
- Possible testicular atrophy
- Acne
- Aggression
Support supplements
Synergies & stacks
Avoid
- SARMs beginners
- Without PCT after cycle
- Underestimating suppression
Sources
Studies and scientific publications this guide relies on.
- Jones A, Chen J, Hwang DJ, et al. (2009). Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. doi: 10.1210/en.2008-0674
Étude préclinique princeps : S-23 est un SARM non stéroïdien à profil androgénique marqué chez le rat, démontre une suppression complète de la spermatogenèse à doses pharmacologiques — initialement développé comme contraceptif masculin.
- Solomon ZJ, Mirabal JR, Mazur DJ, et al. (2019). Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sexual Medicine Reviews. doi: 10.1016/j.sxmr.2018.09.006
Revue systématique : S-23 demi-vie ~12 h, profil suppressif HPTA marqué (le plus suppressif des SARMs courants), élévation ALAT documentée — données humaines absentes hors séries de cas amateurs.
- Bhasin S, Jasuja R (2009). Selective androgen receptor modulators as function promoting therapies. Current Opinion in Clinical Nutrition and Metabolic Care. doi: 10.1097/MCO.0b013e32832a3d79
Revue mécanistique : la classe SARM montre des profils variables d'androgénicité, S-23 figurant parmi les plus androgéniques — d'où sa capacité à supprimer complètement la spermatogenèse, signe d'une activité androgénique tissulaire proche du DHT.
- Pope HG Jr, Wood RI, Rogol A, et al. (2014). Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews. doi: 10.1210/er.2013-1058
Énoncé Endocrine Society : les SARMs récents (S-23, RAD-140, YK-11) sont caractérisés par l'absence presque totale de données cliniques humaines et un signal de suppression HPTA pouvant être profond — usage non encadré, PCT recommandée.
Personalized tracking, dose-response curves and AI advice
Track your cycles with personalized curves based on your weight and profile, tailored AI advice, a daily journal and 59 blood markers.
Free 5-day trial — no credit card